These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 977945)

  • 1. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
    Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
    J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
    Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
    J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
    Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
    J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trinitrophenylated red cells (E-TNP) as a model for antibody-independent activation of the complement system via the classical pathway.
    Loos M; Thesen R
    J Immunol; 1978 Jul; 121(1):24-8. PubMed ID: 670702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation by immunoglobulin does not depend solely on C1q binding.
    Bindon CI; Hale G; Waldmann H
    Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of C1q by monoclonal antibodies.
    Heinz HP; Loos M
    Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
    Betz SJ; Page N; Estrade C; Isliker H
    J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
    van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
    J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement inhibitor(s) released by leukocytes. III. Evidence for a "new" C1 inhibitor in the supernatants of short-term cultures of mouse spleen and thymus cells.
    Bernard A; Boumsell L; Borsos
    J Immunol; 1975 Oct; 115(4):1091-4. PubMed ID: 1176767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement.
    Knutzen Steuer KL; Sloan LB; Oglesby TJ; Farries TC; Nickells MW; Densen P; Harley JB; Atkinson JP
    J Immunol; 1989 Oct; 143(7):2256-61. PubMed ID: 2506280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.
    Kirschfink M; Blase L; Engelmann S; Schwartz-Albiez R
    J Immunol; 1997 Feb; 158(3):1324-31. PubMed ID: 9013976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement inhibitor(s) released by leukocytes. I. Pretreatment of sheep erythrocytes with supernatants of mouse spleen and thymus cells inhibit whole complement activity and C2 utilization.
    Bernard A; Boumsell L; Borsos T; Good RA; Day NK
    J Immunol; 1975 Oct; 115(4):1087-90. PubMed ID: 1176766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.